In addition, data from a small prospective clinical trial enrolling 40 elderly patients with R/R and newly diagnosed FLT3-mutated AML showed high survival rates with azacitidine, venetoclax, and gilteritinib [67], suggesting a survival benefit and safe profile. Here, FLT3 is linked to acute myeloid leukemia.